Progesterone Receptor Negative Recruiting Phase 2 Trials for Olaparib (DB09074)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02849496Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast CancerTreatment
NCT02498613A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsTreatment